COMPASS Pathways $CMPS

Health Care · NASDAQ

United Kingdom
$8.05
-0.60 (-6.94%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Nov 3, 2026, the first target we tracked for CMPS.

COMPASS Pathways (CMPS) is trading down at $8.05 (-6.94%) on NASDAQ, as of the latest quote. It operates in the Health Care sector.

IPO: September 18, 2020 · $17.00 offering · NASDAQ

Analyst price targets on CMPS

One firm's current price target on COMPASS Pathways: $21 — 161% above the current $8.05. Each is tracked to its date and scored the same way a member's call is.

1 target, newest first. Open a row for its source and scoring.

DateNov 3, 2026 FirmStifel RatingBuy · maintains Targetat $8.59 · $21 +144% Horizonby Nov 2027 StatusOpen

Entry price $8.59, the close nearest Nov 3, 2026, when the target was reported; the target is +144% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.

Scoring Open: judged on the close on Nov 3, 2027.

Source Stifel reiterates Compass Pathways stock rating on NDA progress Investing.com · Nov 3, 2026 · opens the publisher's site
Investing.com - Stifel maintained its Buy rating and $21.00 price target on Compass Pathways stock (NASDAQ:CMPS), citing strong execution as the company finalizes its regulatory submission.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

COMPASS Pathways net income history (FY2019–FY2025)

Net income
$0−$143.9M−$287.9MFY2019 net income: −$19.6M'19FY2020 net income: −$60.3M'20FY2021 net income: −$71.7M'21FY2022 net income: −$91.5M'22FY2023 net income: −$118.5M'23FY2024 net income: −$155.1M'24FY2025 net income: −$287.9M'25
COMPASS Pathways annual financial statements
FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Operating income−$21.2M−$51.4M−$83.2M−$110.4M−$136.9M−$178.2M−$179.0M
Net income−$19.6M−$60.3M−$71.7M−$91.5M−$118.5M−$155.1M−$287.9M
EPS (diluted)−$2.62−$3.55−$1.79−$2.16−$2.32−$2.30−$3.08
Balance sheet
Cash and equivalents$25.0M$190.3M$273.2M$143.2M$220.2M$165.1M$149.6M
Total assets$32.4M$203.5M$300.9M$197.3M$276.0M$213.7M$210.3M
Total liabilities$23.9M$6.89M$16.5M$16.0M$50.2M$59.0M$263.2M
Long-term debt———$0$28.8M$24.7M$14.1M
Shareholders' equity−$30.4M$196.6M$284.4M$181.3M$225.7M$154.7M−$52.8M
Cash flow
Operating cash flow−$17.8M−$41.4M−$67.7M−$105.5M−$97.4M−$119.2M−$157.2M
Capital expenditure$165.0K$131.0K$334.0K$596.0K$66.0K$0—
Free cash flow−$18.0M−$41.5M−$68.1M−$106.0M−$97.4M−$119.2M—

From COMPASS Pathways's 10-K, 10-Q, 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

COMPASS Pathways in the news

Nov 18, 2026 Investing.com COMPASS Pathways at Jefferies: psilocybin launch plan takes shape
Nov 3, 2026 Investing.com Compass Pathways stock maintained at Buy by TD Cowen ahead of NDA filing
Nov 3, 2026 Investing.com Stifel reiterates Compass Pathways stock rating on NDA progress Target
Oct 11, 2026 Stocktwits Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms

Also mentions Advanced Micro Devices, SpaceX, Alphabet Inc. (Class A), Intellia Therapeutics Inc, Crispr Therapeutics AG

Oct 10, 2026 TradingView Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms

Also mentions Advanced Micro Devices, SpaceX, Alphabet Inc. (Class A), Intellia Therapeutics Inc, Crispr Therapeutics AG

Show 1 older story
Sep 16, 2026 Investing.com COMPASS Pathways at Morgan Stanley conference: launch, data and FDA push

About COMPASS Pathways

Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), has completed phase 3 clinical trials for treatment-resistant depression. The results showed clear benefit to participants as measured on the MADRS depression rating scale. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration (FDA). It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine (MDMA).

Source: Wikipedia — Compass Pathways

Headquarters
Chesire, United Kingdom From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →

Mentioned with COMPASS Pathways in recent news